BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Objectives Erdheim-Chester disease (ECD) is a rare form of histiocytosis characterised by uncontrolled chronic inflammation. The oncogenic BRAF(V600E) mutation has been reported in biopsies in 19 out of 37 patients with ECD from the largest published cohort, but never found in the patients' peripheral blood. Also, the role of the mutation in the pathogenesis of the disease has not been elucidated yet. BRAF(V600E) has been associated with oncogene-induced senescence (OIS), a protective mechanism against oncogenic events, characterised by the induction of proinflammatory pathways. Methods We verified the BRAF status in biopsies and peripheral blood from 18 patients with ECD from our cohort and matched controls by means of immunohistochemistry and of an ultrasensitive assay, based on the combination of a locked nucleic acid PCR and pyrosequencing. Droplet digital PCR was used to confirm the findings. We also evaluated the presence of senescence markers in ECD histiocytes. Results BRAF(V600E) mutation was present in all the biopsy and peripheral blood samples from patients with ECD and in none of the controls. ECD histiocytes and a fraction of circulating monocytes from patients with ECD showed signs of a constitutive activation of the MAPK pathway. Moreover, BRAF-mutated histiocytes expressed markers of OIS. Conclusions The oncogenic BRAF(V600E) mutation is present in biopsies and in the peripheral blood from all patients with ECD who were evaluated and is associated with OIS. T…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Macrophages with senescence-like features have also been identified in lesions from patients with cell histiocytoses, haematological neoplasms associated with oncogene activation characterized by multiorgan dissemination of highly inflamed, p16-positive myeloid cells177,178.”
From Cellular senescence in ageing: from mechanisms to therapeutic opportunities (2021) · cites this paper as [178]
Citations
Cites
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
A complex secretory program orchestrated by the inflammasome controls paracrine senescence
Acosta, J. C., Banito, A., Wuestefeld, T., Georgilis, A., Janich, P., Morton, J. P., Athineos, D., Kang, T.-W., Lasitschka, F., Andrulis, M., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2784 · Cited by 2,278
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,160
BRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160
Oncogene-Induced Senescence Relayed by an Interleukin-Dependent Inflammatory Network
Kuilman, T., Michaloglou, C., Vredeveld, L. C. W., Douma, S., van Doorn, R., Desmet, C. J., Aarden, L. A., Mooi, W. J., & Peeper, D. S. (2008) · Cell · doi:10.1016/j.cell.2008.03.039 · Cited by 2,086
Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-63198 · Cited by 1,330
Recurrent BRAF mutations in Langerhans cell histiocytosis
Badalian-Very, G., Vergilio, J.-A., Degar, B. A., MacConaill, L. E., Brandner, B., Calicchio, M. L., Kuo, F. C., Ligon, A. H., Stevenson, K. E., Kehoe, S. M., et al. (2010) · Blood · doi:10.1182/blood-2010-04-279083 · Cited by 1,243
BRAF Mutations in Hairy-Cell Leukemia
Tiacci, E., Trifonov, V., Schiavoni, G., Holmes, A., Kern, W., Martelli, M. P., Pucciarini, A., Bigerna, B., Pacini, R., Wells, V. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014209 · Cited by 1,024
Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
Ho, A. L., Grewal, R. K., Leboeuf, R., Sherman, E. J., Pfister, D. G., Deandreis, D., Pentlow, K. S., Zanzonico, P. B., Haque, S., Gavane, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209288 · Cited by 843
Cited by
Cellular senescence in ageing: from mechanisms to therapeutic opportunities
Di Micco, R., Krizhanovsky, V., Baker, D., & d’Adda di Fagagna, F. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00314-w · Cited by 2,277
Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease
Diamond, E. L., Dagna, L., Hyman, D. M., Cavalli, G., Janku, F., Estrada-Veras, J., Ferrarini, M., Abdel-Wahab, O., Heaney, M. L., Scheel, P. J., et al. (2014) · Blood · doi:10.1182/blood-2014-03-561381 · Cited by 586
“The highly variable histiocyte content present in many ECD biopsy samples influences BRAF mutational testing results.(11) Moreover, the frequency of bone biopsies in ECD presents additional challenge to identifying of BRAFmutations.”
BackgroundSelf-citationAnakinra Therapy for Non-cancer Inflammatory Diseases
Cavalli, G., & Dinarello, C. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01157 · Cited by 292
“The disease is typically sustained by activating mutations along the mitogen-activated protein kinase (MAPK) or related pathways in macrophages, which lead to cell activation and consequent production of high levels of pro-inflammatory cytokines and fibrosis of affected tissues (Cavalli et al., 2014; Cangi et al., 201…”
BackgroundSelf-citationHaroche, J., Cohen-Aubart, F., Emile, J.-F., Maksud, P., Drier, A., Tolédano, D., Barete, S., Charlotte, F., Cluzel, P., Donadieu, J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.1950 · Cited by 289
Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease
Emile, J.-F., Diamond, E. L., Hélias-Rodzewicz, Z., Cohen-Aubart, F., Charlotte, F., Hyman, D. M., Kim, E., Rampal, R., Patel, M., Ganzel, C., et al. (2014) · Blood · doi:10.1182/blood-2014-04-570937 · Cited by 244
“In addition, several groups have noted that a larger proportion of LCH and ECD lesions have activation of ERK signaling than demonstrated to have the BRAFV600E mutation3,8,9 Interestingly, Cangi et al. recently identified that 18/18 ECD patients had a BRAFV600E mutation in DNA from whole lesional tissue if an ultrasen…”
Background
Metadata
- Authors
- Cangi, M. G., Biavasco, R., Cavalli, G., Grassini, G., Dal-Cin, E., Campochiaro, C., Guglielmi, B., Berti, A., Lampasona, V., von Deimling, A., Sabbadini, M. G., Ferrarini, M., Doglioni, C., & Dagna, L.
- Affiliations
- IRCCS Ospedale San Raffaele (IT)
- Vita-Salute San Raffaele University (IT)
- Corresponding author
- Dagna, Lorenzo
- ORCID
- Venue
- Annals of the Rheumatic Diseases
- Publisher
- Elsevier BV
- Published
- 2015-08
- Volume
- 74
- Issue
- 8
- Pages
- 1596-1602
- ISSN
- 0003-4967 (ISSN-L)
- OpenAlex
- W1968011285
- Cited by
- 112
- References
- 44
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 6 · 2023: 9 · 2022: 8 · 2021: 4 · 2020: 10 · 2019: 8 · 2018: 12 · 2017: 12 · 2016: 15 · 2015: 10
- FWCI
- 10.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- Annals of the Rheumatic Diseases (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Iris (University of Trento) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Histiocytic Disorders and Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Sarcoidosis and Beryllium Toxicity Research
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Keywords
- Erdheim-Chester disease, BRAF V600E mutation, oncogene-induced senescence, histiocytosis, histiocytes, MAPK pathway activation, peripheral blood, circulating monocytes, senescence markers, chronic inflammation, pathogenesis
- MeSH terms
- Adult, Aged, Female, Histiocytes, Humans, Immunohistochemistry, Inflammation, Leukocytes, Mononuclear, Male, Middle Aged, Mutation, Oncogenes, Polymerase Chain Reaction, Cellular Senescence, Sequence Analysis, Erdheim-Chester Disease, Proto-Oncogene Proteins B-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease. https://app.cochat.ai/papers/10.1136/annrheumdis-2013-204924
- The paper
- Cangi, M. G., Biavasco, R., Cavalli, G., Grassini, G., Dal-Cin, E., Campochiaro, C., Guglielmi, B., Berti, A., Lampasona, V., von Deimling, A., Sabbadini, M. G., Ferrarini, M., Doglioni, C., & Dagna, L. (2015). BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2013-204924
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.